The United Kingdom Continuous Glucose Monitoring Market is expected to register a CAGR of about 15.9% and reach a value of about USD 580 million over the forecast period.
According to The British Diabetic Association, the COVID-19 pandemic continued to have a huge impact on society. However, research and data showed that people with diabetes were disproportionately affected by COVID-19, particularly in terms of poorer outcomes when contracting the virus; that's why preventing or delaying cases of diabetes was more important than ever. The pandemic also highlighted opportunities for continuing and expanding innovations in the delivery of diabetes care through virtual consultations between healthcare providers and people with diabetes and diabetes technology. Crisis management has created unprecedented interest in remote care from both patients and providers.
Continuous Glucose Monitoring tests glucose concentration in the blood (glycemia). Particularly important in diabetes management, a blood glucose test is typically performed to determine the fluctuation in blood glucose level to take or alter the medication accordingly, especially for insulin users. Achieving optimum glycemic results can be very difficult without frequent monitoring of blood glucose levels.
Furthermore, the current continuous glucose Monitoring can either retrospectively display the trends in blood glucose levels by downloading the data or give a real-time picture of glucose levels through receiver displays. The newest CGM models, the Abbott Freestyle Libre 3 and the Dexcom G7, overcame many technical barriers. Technological advances such as Eversense E3 CGMs have significantly improved the ability of providers and patients to manage diabetes, thereby enhancing the market prospects in the years to come.
In the United Kingdom, the prevalence of diabetes has increased dramatically during the last two decades, driven by the increased prevalence of obesity and lifestyle changes. The country also has the highest obese population, a prominent cause of Type 2 diabetes. According to The British Diabetic Association Diabetes Prevalence, the latest data shows an increase in the number of people living with a diabetes diagnosis in the United Kingdom: an increase of more than 150,000 from the previous year. It is estimated that more than 13.6 million people are at increased risk of type 2 diabetes in the United Kingdom. At this rate, the number of people with diabetes, including the undiagnosed population, is expected to rise to 5.5 million by 2030, as per IDF 2021 statistics.
The rapidly increasing incidence and prevalence of diabetic patients and healthcare expenditure are indications of market growth. Leading manufacturers focus on technological innovations and develop advanced products to gain a substantial market share. Technological innovations and advancements offer many conveniences in maintaining blood glucose levels. The vast range of apps in the diabetes field supports the adoption of lifestyle interventions for the prevention and management of diabetes, the evaluation of blood glucose control quality, and the dosing of insulin. Integration of Continuous Glucose Monitoring with insulin calculators, automated insulin titration software, and remote coaching are further developments that provide patients with poorly controlled diabetes additional support needed to improve critical outcomes, thereby enhancing the market prospects in the years to come.
Continuous Glucose Monitoring Devices are automated glucose monitoring systems that consist of a small device that can be worn on the body and held on by an adhesive patch. The sensor part of the device has a cannula inserted into the top layer of skin and uses interstitial fluid samples to check glucose levels. Sensors are connected to a transmitter that can send data wirelessly to a dedicated mobile receiving device or smartphone. Continuous Glucose Monitoring sensors use glucose oxidase to detect blood sugar levels. Sensors are the most important part of Continuous Glucose Monitoring devices.
Researchers are trying to find and develop alternatives to electrochemical-based glucose sensors and create more affordable, minimally invasive, and user-friendly CGM sensors. Optical measurement is a promising platform for glucose sensing. Some technologies have been reported to have high potential in continuous glucose sensing, including spectroscopy, fluorescence, holographic technology, etc. Eversense, a CGM sensor based on fluorescence sensing developed by Senseonics Company, has a much longer lifespan than electrochemical sensors. Technological advancements to improve the accuracy of the sensors are expected to drive segment growth during the forecast period.
The National Service Framework (NSF) program is improving services by setting national standards to drive service quality and tackle variations in care. The Association of British HealthTech Industries (ABHI) launched a diabetes section, enabling diabetes technology companies to work together in the first forum of its kind. The ABHI group is for any health technology company interested in diabetes care, from CGM and insulin pumps to apps. Such advantages are likely to drive segment growth over the forecast period.
This product will be delivered within 2 business days.
According to The British Diabetic Association, the COVID-19 pandemic continued to have a huge impact on society. However, research and data showed that people with diabetes were disproportionately affected by COVID-19, particularly in terms of poorer outcomes when contracting the virus; that's why preventing or delaying cases of diabetes was more important than ever. The pandemic also highlighted opportunities for continuing and expanding innovations in the delivery of diabetes care through virtual consultations between healthcare providers and people with diabetes and diabetes technology. Crisis management has created unprecedented interest in remote care from both patients and providers.
Continuous Glucose Monitoring tests glucose concentration in the blood (glycemia). Particularly important in diabetes management, a blood glucose test is typically performed to determine the fluctuation in blood glucose level to take or alter the medication accordingly, especially for insulin users. Achieving optimum glycemic results can be very difficult without frequent monitoring of blood glucose levels.
Furthermore, the current continuous glucose Monitoring can either retrospectively display the trends in blood glucose levels by downloading the data or give a real-time picture of glucose levels through receiver displays. The newest CGM models, the Abbott Freestyle Libre 3 and the Dexcom G7, overcame many technical barriers. Technological advances such as Eversense E3 CGMs have significantly improved the ability of providers and patients to manage diabetes, thereby enhancing the market prospects in the years to come.
United Kingdom Continuous Glucose Monitoring Market Trends
Growing Diabetes Population in the United Kingdom
The United Kingdom diabetes Population is expected to increase with a CAGR greater than 2% over the forecast period.In the United Kingdom, the prevalence of diabetes has increased dramatically during the last two decades, driven by the increased prevalence of obesity and lifestyle changes. The country also has the highest obese population, a prominent cause of Type 2 diabetes. According to The British Diabetic Association Diabetes Prevalence, the latest data shows an increase in the number of people living with a diabetes diagnosis in the United Kingdom: an increase of more than 150,000 from the previous year. It is estimated that more than 13.6 million people are at increased risk of type 2 diabetes in the United Kingdom. At this rate, the number of people with diabetes, including the undiagnosed population, is expected to rise to 5.5 million by 2030, as per IDF 2021 statistics.
The rapidly increasing incidence and prevalence of diabetic patients and healthcare expenditure are indications of market growth. Leading manufacturers focus on technological innovations and develop advanced products to gain a substantial market share. Technological innovations and advancements offer many conveniences in maintaining blood glucose levels. The vast range of apps in the diabetes field supports the adoption of lifestyle interventions for the prevention and management of diabetes, the evaluation of blood glucose control quality, and the dosing of insulin. Integration of Continuous Glucose Monitoring with insulin calculators, automated insulin titration software, and remote coaching are further developments that provide patients with poorly controlled diabetes additional support needed to improve critical outcomes, thereby enhancing the market prospects in the years to come.
The sensors segment is expected to hold the highest share over the forecast period
The sensors segment is expected to register a CAGR of 15.8% over the forecast period.Continuous Glucose Monitoring Devices are automated glucose monitoring systems that consist of a small device that can be worn on the body and held on by an adhesive patch. The sensor part of the device has a cannula inserted into the top layer of skin and uses interstitial fluid samples to check glucose levels. Sensors are connected to a transmitter that can send data wirelessly to a dedicated mobile receiving device or smartphone. Continuous Glucose Monitoring sensors use glucose oxidase to detect blood sugar levels. Sensors are the most important part of Continuous Glucose Monitoring devices.
Researchers are trying to find and develop alternatives to electrochemical-based glucose sensors and create more affordable, minimally invasive, and user-friendly CGM sensors. Optical measurement is a promising platform for glucose sensing. Some technologies have been reported to have high potential in continuous glucose sensing, including spectroscopy, fluorescence, holographic technology, etc. Eversense, a CGM sensor based on fluorescence sensing developed by Senseonics Company, has a much longer lifespan than electrochemical sensors. Technological advancements to improve the accuracy of the sensors are expected to drive segment growth during the forecast period.
The National Service Framework (NSF) program is improving services by setting national standards to drive service quality and tackle variations in care. The Association of British HealthTech Industries (ABHI) launched a diabetes section, enabling diabetes technology companies to work together in the first forum of its kind. The ABHI group is for any health technology company interested in diabetes care, from CGM and insulin pumps to apps. Such advantages are likely to drive segment growth over the forecast period.
United Kingdom Continuous Glucose Monitoring Industry Overview
The United Kingdom Continuous Glucose Monitoring Market is consolidated, with few significant players. There have been constant innovations driven by manufacturers such as Abbott, Dexcom, Medtronic, etc., while also adhering to organic growth strategies, which is evident from the R&D spending of these companies.Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1 INTRODUCTION
4 MARKET DYNAMICS
5 MARKET SEGMENTATION
6 MARKET INDICATORS
7 COMPETITIVE LANDSCAPE
Methodology
LOADING...
